P-selectin is a 140-kD protein found in the a-granules of platelets and the Weibel-Palade bodies o f endothelial cells that on cell activation is expressed on the cell surface and also secreted into the plasma. The secreted form of P-selectin, like plasma P-selectin, differed from platelet membrane P-selectin in that its molecular mass was "3 kD lower under reducing conditions. Both the secreted and plasma forms of P-selectin contained cytoplasmic sequence as determined by Western blot analysis with an affinity-purified rabbit anti-P-selectin cytoplasmic peptide antibody, We have measured plasma P-selectin and j3-thromboglobulin (BTG) concurrently in (1) patients with consumptive thrombotic disorders, including disseminated intravascular coagulation (DIC), heparin-induced thrombocytopenia (HIT), and thrombotic thrombocytopenic purpura (TTP)/haemolytic uremic syndrome (HUS); (2) pa-SELECTIN OR GMP-140 is an integral membrane glycoprotein localized to the a-granules of platelets and Weibel-Palade bodies of endothelial cells.' Other names given to this protein include PADGEM (platelet activation dependent granule-external membrane protein)' and CD62. It is a member of a family of cell adhesion receptors termed selectins that mediate one or more aspects of leukocyte adhesion. The selectins share a common structural theme, ie, an N-terminal lectin domain, an epidermal growth factor motif, a variable number of "complementregulatory protein" repeats, a transmembrane domain, and a short cytoplasmic taiL3
SELECTIN OR GMP-140 is an integral membrane glycoprotein localized to the a-granules of platelets and Weibel-Palade bodies of endothelial cells.' Other names given to this protein include PADGEM (platelet activation dependent granule-external membrane protein)' and CD62. It is a member of a family of cell adhesion receptors termed selectins that mediate one or more aspects of leukocyte adhesion. The selectins share a common structural theme, ie, an N-terminal lectin domain, an epidermal growth factor motif, a variable number of "complementregulatory protein" repeats, a transmembrane domain, and a short cytoplasmic taiL3
Recently, endothelial P-selectin has been cloned and the cloning data predicted three different forms of the protein, including a soluble form that lacks a transmembrane domain. 3 Dunlop et ai4 have successfully purified the soluble P-selectin from human plasma and showed a molecular mass approximately 3 kD lower than that of membrane P-selectin when analyzed on sodium dodecyl sulfate (SDS)-polyacrylamide gels under reduced conditions. When platelets and endothelial cells are activated, P-selectin is expressed on the cell surface' and has been demonstrated in in vivo thrombus.' P-selectin has also been shown to be secreted from activated platelets4 and both platelets and endothelial cells contain mRNA encoding the soluble form of P-selectin. 6 An increase in plasma P-selectin concentration may therefore indicate in vivo activation/damage of platelets and endothelial cells. Plasma P-selectin may be a clinically useful marker of thrombotic diseases in which one or more of these in vivo processes are prominent,
The most reliable methods for the detection of in vivo platelet activation and endothelial cell perturbation at the present time are assays of platelet a-granule proteins such as platelet factor 4 (PF4) and 8-thromboglobulin (pTG) and metabolites of thromboxane A2 and prostacyclin in the plasma or ~r i n e .~-~ Because of the technical limitations pertaining to sample collection, processing, and analysis, these assays have not gained widespread clinical usage as markers of thrombotic disorders. Flow cytometry has been recently used to detect circulating activated platelets using fluores- tients with idiopathic thrombocytopenic purpura (ITP); and (3) healthy controls. Patients with DIC, HIT, and TTP/HUS, but not ITP, had significantly elevated plasma P-selectin and j3TG levels when compared with their age-matched healthy controls. The increased plasma P-selectin and BTG in patients with thrombotic disorders were likely to be the result of in vivo platelet and endothelial cell damage or activation. We also found that avoidance of veno-occlusion and other tedious measures customarily taken during blood collection and sample preparation to prevent in vitro platelet activation did not affect plasma P-selectin assay results. In addition, plasma P-selectin levels were not influenced by the presence of renal failure or heparin administration. These results indicate that plasma P-selectin may be a useful new marker for thrombotic diseases. 0 1994 by The American Society of Hematology.
cein-labeled monoclonal antibodies (MoAbs) such as PAC 1, which reacts with the activated form of platelet glycoprotein (GP) IIb-IIIa; 9F9, which is specific for platelet bound fibrinogen; and S12, which binds to P-selectin expressed on activated platelets.'o~'' However, activated platelets may be cleared more rapidly from the circulation; hence, assays dependent on their detection may be less sensitive than those measuring platelet release products in
In this study, we have further characterized the plasma and secreted forms of P-~electin.~ In addition, we report increased plasma P-selectin levels that were detected simultaneously with increased plasma pTG concentrations in patients with consumptive thrombotic disorders such as disseminated intravascular coagulation (DIC), thrombotic thrombocytopenic purpura (TTP), hemolytic uremic syndrome (HUS), and heparin-induced thrombocytopenia (HIT). In these thrombotic disorders, activation/damage of platelets and endothelial cells are known to occur and these findings suggest that plasma P-selectin could be a clinically useful marker for thrombotic diseases. In addition, we provide evidence that, unlike plasma @TG and PF4 assays, measurement of plasma P-selectin is not influenced by blood collection and sample preparation procedures, impaired renal function, or heparin administration, indicating that P-selectin estimation has potential advantages over other methods.
SUBJECTS AND METHODS

Patients With Consumptive Thrombotic Disorders
DIC. Twenty-one patients with DIC were studied, including 14 males and 7 females, with ages ranging from 24 to 99 years (mean, 58 years). They had reduced plasma fibrinogen (mean k SD, I .2 k 0.6 g/L), elevated d-dimer (mean k SD, 1.8 k 0.6 mg/L), thrombocytopenia (mean platelet count k SD, 63 * 30 X 109/L), prolonged activated partial thromboplastin time (APTT) and/or prothrombin times, and a predisposingcause for DIC, which included sepsis, cancer, heatstroke, and obstetric accidents.14 HIT. Twenty-one patients with HIT (8 males and 13 females) whose ages ranged from 39 to 83 years (mean age, 58 years) were studied. They fulfilled the following diagnostic criteria: ( I ) a normal platelet count before heparin treatment; (2) thrombocytopenia (mean platelet count k SD, 58 k 28 X 109/L) occurring during heparin therapy; (3) exclusion of other causes of thrombocytopenia; and (4) a heparindependent antiplatelet antibody detected in the patients' sera/plasma by platelet aggreg~metry.'~ Twelve patients had acute arterial and/or venous thrombosis.
TTP/HUS. Three patients with TTP and 2 with HUS (1 male and 4 females) were included in the study. Their ages ranged from 5 to 56 years (mean, 48 years). They had thrombocytopenia, microangiopathic hemolytic anemia, and impaired renal function. In addition, the patients with TTP had fever and neurologic manifestations such as coma and fits.14 The patients with TTP had been treated with aspirin and dipyridamole before the blood was sampled.
Patients With Idiopathic Thrombocytopenic Purpura (fTP)
Twenty-one patients with ITP ( I O males and I 1 females) were studied as controls because in vivo platelet activation and endothelial cell perturbation is uncommon in this disorder. Their ages ranged from 2 l to 94 years (mean, 52 years). They had a nonpalpable spleen, normal or increased number of megakaryocytes in the bone marrow aspirate, and a thrombocytopenia for which all other causes were excluded by clinical features and laboratory investigations. 16 
Patients With Chronic Renal Failure
Twenty-four patients with stable chronic renal failure between the age of 25 to 92 years (mean, 54 years) were studied. They had varying degrees of renal impairment, with plasma creatinine ranging from 0.12 to 1.25 mmol/L, normal platelet counts, and no clinical thrombosis.
Healthy Controls
Thirty-nine healthy controls (22 females and I7 males) were studied. Their ages ranged from 22 to 90 years (mean, 55 years), with 23 below and I4 above 60 years of age.
Blood Collection and Plasma Preparation
Blood was collected from patients and controls without veno-occlusion, using a 19-gauge butterfly needle and two-syringe technique, as previously described." The blood was collected in polypropylene tubes containing 0.5 mL of anticoagulant mixture, ETP (1 10 mmol/L disodium EDTA, 12 mmol/L theophylline, and 2.82 pmol/L prostaglandin E, [PGE,]). The blood was immediately kept cold in melting ice until it was centrifuged and the plasma was removed. 17 To investigate the influence ofblood collection and preparation procedures on plasma P-selectin assay levels, in some experiments a certain step(s) in the above procedure was deliberately omitted or altered. Additionally, blood was processed in the same manner as platelet-poor plasma would be prepared for routine blood coagulation tests, as previously described. 15 Informed consent for blood collection was obtained from every patient and normal volunteer. All subjects, except the patients with TTP, did not take any medications that may inhibit platelet function for at least 10 days before their participation in the study.
Polyclonal Antibodies
The preparation of an affinity-purified rabbit polyclonal antihuman P-selectin antibody has been previously described in Antipeptide antibodies were raised in New Zealand white rabbits using peptide-keyhole limpet hemocyanin (KLH) conjugates. Peptide sequences selected from the transmembrane (exon 14) and cytoplasmic domains (exon 15) of P-selectin were made to specification by Auspep Pty Ltd (Melbourne, Australia). The transmembrane domain peptide was CALLRKKRQK, with the N-terminal cysteinyl residue added to allow coupling to KLH. The cytoplasmic domain peptide was CPLNPHSHLGT. Both peptides contained free N-and C-termini. Peptides were coupled to KLH using m-Maleimidobenzoyl-N-hydroxysuccinimide ester (MBS), as previously described." For the initial subcutaneous injection, the peptide-KLH conjugate (1 mg in 1 mL) was mixed with Freund's complete adjuvant. At 3-weekly intervals, two booster innoculations were similarly performed, but with Freund's incomplete adjuvant. Antipeptide antibodies were affinity-purified using a 1 X 10 cm column ofpeptide-bovine serum albumin conjugate coupled to a mixture of Affigels 10 and 15 (Bio-Rad, Richmond, CA). Bound antibody was eluted with 0. I mol/L glycine, pH 2.4, and immediately neutralized by the addition of 0.2 v01 of 1 mol/L Tris, pH 8.0. The eluted Ig was dialysed exhaustively against 0.0 1 mol/L Tris, 0. I5 mol/L sodium chloride, pH 7.4, and stored at -70°C.
P-Selectin and PTG Assays
The P-selectin assay was performed using a sandwich enzymelinked immunosorbent assay and the plasma PTC assay was performed using a rabbit anti-PTC antibody, both as previously described in detail. 17 The latter was performed on the same plasma samples on which P-selectin was assayed.
Plasma samples for PTC and P-selectin assays were collected within 3 days of diagnosis of DIC, HIT, TTP/HUS, and I T P in 5 of these patients with HIT, serial samples were also collected at regular intervals for about 10 days.
Pulse Radioiodination of a-Thrombin-Treated Platelets
Washed piatelets were 0-thrombin activated and pulse radioiodinated essentially as previously described.20 Briefly, washed platelets were activated with a-thrombin ( I U/mL, final concentration) in the presence of Na 1251 (1 mCi/mL) and lactoperoxidase (2.5 fig/ mL), and 30 seconds later the platelet suspension was made 35 pmol/L in hydrogen peroxide. ARer a further 30 seconds, the radioiodination was terminated by the addition of catalase (3.5 pmol/L, final concentration). The platelets were then pelleted by centrifugation at l ,000g for l5 minutes. The supernatant was recentrifuged at 8,370g for 5 minutes and then at 100,OOOg for 3 hours. The platelet pellet was resuspended at IO9 platelets/mL in HEPES buffer for immunoprecipitation analysis.
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From
Analytical Methods
SDSpolyacrylamide gel electrophoresis (SDS-PAGE), immunoprecipitation analysis, and Western blot analysis were performed as previously dexribed in detail.'*.*'
Statistical Analysis
Statistical analysis was performed, unless otherwise stated, using the Mann Whitney U test. Spearman's rank correlation test was used to analyze the relationship between plasma P-selectin and P G , and, in patients with chronic renal failure, between plasma Pselectin and creatinine and plasma P G and creatinine. The results were expressed as medians and absolute ranges, with the latter in parenthesis.
RESULTS
Plasma/Secreted Form of P-Selectin
We have previously shown that a soluble form of P-selectin circulates in plasma and can be secreted from activated platelets? On SDS-polyacrylamide gels, the plasma form of P-selectin had an identical molecular mass to platelet membrane P-selectin under nonreducing conditions, but was "3 kD smaller under reducing conditions. Analytical gel filtration analysis indicated that the plasma form of P-selectin eluted as a monomer, whereas detergent-free, platelet membrane P-selectin eluted primarily as a tetramer. Both these findings are consistent with plasma P-selectin lacking an hydrophobic transmembrane sequence and are consistent with its potential derivation from the alternatively spliced form of P-selectin lacking exon 14.that encodes the transmembrane d~m a i n .~.~ Both platelets and endothelial cells have been shown to contain mRNA encoding the soluble form of P-selectin! In this study, additional experiments were performed to further characterize the platelet-secreted and plasma forms of P-selectin.
Because the rabbit affinity-purified anti-P-selectin antibody does not recognize reduced P-selectin after SDS-PAGE, we pulse radioiodinated platelets between 30 and 60 seconds after the addition of a-thrombin as a platelet stimulus. Immunoprecipitation of the washed and detergentlysed platelet pellet with polyclonal anti-P-selectin antibody demonstrated that P-selectin had been surface expressed within the first minute ofplatelet activation (Fig 1 A, lane 2) . Radiolabeled P-selectin could also be immunoprecipitated from the ultracentrifuged supernatant ofthese thrombin activated platelets (Fig 1 A, lane 3) . As is the case for plasma Pselectin, the P-selectin in the ultracentrifuged supernatant from these platelets had a lower molecular mass ( " 3 kD) under reducing conditions than the P-selectin that was platelet membrane associated (Fig IA) , although the molecular size was similar under nonreducing conditions (data not shown and Dunlop et aI4).
A polyclonal antibody directed against a P-selectin cytoplasmic peptide (sequence within that defined by exon 15) Western-blotted purified platelet membrane P-selectin under nonreducing and reducing conditions (data not shown) B + + + Platelets were treated with a-thrombin and surface radioiodinated between 30 and 60 seconds after thrombin addition. The supematant from these platelets was then ultracentrifuged. Subsequent immunoprecipitation of the washed, detergent-lysed platelet pellet and the ultracentrifuged supernatant was performed using an affinity-purified rabbit polyclonal anti-P-selectin antibody (lanes 2 and 3, respectively) or nonimmune rabbit lg (lanes 1 and 4, respectively) . There were significant difference6 between (l ) P-selectin levels of healthy wntrols (CON-and patients with HIT, DIC, and HUS/TTP (HIT: <60 yr P < .02. >6O yr P < .00001: DC: <BO yrs P < .00001, >60 yr P < .0002; HUS/TTP: P < .0005) and (2) gfG levels of healthy controls and patients with HIT, DIC, and HUS/TTP (HIT: <60 yr P < .02, >60 yr P < .00001; OIC: <60yr P < .005, >60 yr P < .0005; HUSITTP: P < .001). Among the healthy controls, those aged over 60 years had higher P-selectin and j3TG concentrations than those below 60 years f P < .005 and P < .0001, respectiveb). (0) < 60 years: (e) > 60 years.
and P-selectin in whole platelets (Fig IB, lane 1 ). An additional band of unknown derivation was seen at -95 kD. This antibody recognized the secreted form of P-selectin in the platelet supernatant both before (Fig IC, lane 2) and after ultracentrifugation of the supernatant at 100,OOOg for 3
hours (Fig IC, lane 3) . Interestingly, although only -15% of the total platelet P-selectin pool is secreted on activation (calculated from Dunlop et all4), the anti-P-selectin cytoplasmic peptide antibody reacted more strongly with secreted P-selectin than with the P-selectin, which remained platelet associated (Fig lC, lanes 2 and 3 v lane 1) . This difference in immunoreactivity versus relative amount was abo observed with purified plasma P-selectin, which also reacted more strongly than platelet membrane P-selectin with this antibody (data not shown). Because there are only 11 intervening amino acids in the P-selectin sequence between the cytoplasmic peptide used as the immunogen and the putative transmembrane spanning ~e p t i d e ,~ the difference in immunoreactivity may reflect relative epitope access on nitrocellulose depending on whether the transmembrane domain encoded by exon 14 is present or not. Unfortunately, the antipeptide antibody directed against the peptide sequence within exon 14 did not recognize intact platelet membrane P-selectin and therefore could not be used to fully define the derivation of the secreted and plasma forms of P-selectin.
Plasma Concentrations of P-Selectin in Healthy Controls and Patienls
The plasma levels of P-selectin and PTG of 37 healthy controls are shown in Fig 2. The median plasma P-selectin value of the healthy subjects was 0.2 1 MglmL {range, 0.09 to 0.40 pg/mL) and the median plasma PTG level was 18.3 ng/ m L (range, 9.0 to 39.5 ng/mL). Plasma P-selectin and /fTG levels of the healthy controls aged more than 60 years were significantly higher than those aged less than 60 years. However, there was no significant difference in plasma P-selectin or PTG values between the male and female subjects. As shown in Fig 2, plasma P-selectin and BTG levels of the patients with DIC, HIT, and TTP/HUS were substantially higher than those of the age-matched heakhy subjects, with little overlap between the patients' and the controls' values. In contrast, the plasma P-selectin and PTG values of For personal use only. on November 16, 2017. by guest www.bloodjournal.org From Experiments were also performed to investigate whether measures customarily taken to prevent in vitro platelet activation and sample contamination by platelets/platelet dust are necessary for assays ofplasma P-selectin. Both P-selectin and BTG were assayed in plasma from 10 healthy subjects prepared with these preventive measures and compared with the plasma of the same subjects prepared with one of these measures selectively omitted. It was found that the omission of any one of the measures, ie, (1) potent platelet inhibitors (ETP), (2) maintainance of the sample temperature at 0°C to 4"C, and (3) either ultracentrifugation or centrifugation three times at 12,300g for 5 minutes to remove platelets/platelet dust, resulted in a significant increase of BTG values (Table 1) . In contrast, omission of these measures did not cause an increase in P-selectin values. Plasma samples processed without these measures and, in the same manner as samples for routine coagulation tests, gave P-selectin values that did not differ significantly from those processed with these measures (P > .01). This finding is in agreement with that of Dunlop et a1," who also found that P-selectin plasma levels were insensitive to collection procedure or speed of centrifugation.
To investigate whether renal failure affects plasma concentrations of f l G and P-selectin, plasma levels of these proteins were measured in 24 patients with varying degrees of renal failure but without clinical evidence of thrombosis or platelet consumption. There was no correlation between plasma P-selectin and creatinine levels (Spearman's test, r = .206, P > .l), whereas plasma D G and creatinine values were closely correlated (Spearman's test, r = .64 1, P < .002) (Fig 4) . In addition, plasma P-selectin levels were found to be unaffected by heparin administration. There was no significant increase in plasma P-selectin when heparin (5,000 IU) was injected intravenously into 3 subjects ( Table 2) .
DISCUSSION
A previous study from our laboratory showed that P-selectin was secreted from activated platelets and also circulated in plasma at a concentration of -0.2 ~g / m L .~ In this study, we found that the secreted form of P-selectin, similar to plasma P-selectin, differed from platelet membrane P-selectin in that it had a slightly lower molecular mass by -3 kD under reducing conditions. Both the plasma and secreted forms of P-selectin immunoblotted with an anti-Pselectin cytoplasmic peptide antibody, excluding the possibility that they are derived by proteolysis of the extracellular portion of platelet membrane P-~electin.~ P-selectin is known to be a major constituent of platelet dust or microparticles, which are formed on platelet activation and also circulate in plasma. However, the following evidence suggests that the secreted and plasma forms of P-selectin we have described are probably not associated with platelet membrane microparticles. First, as discussed above, both these forms of P-selectin are smaller in molecular weight than platelet membrane P-selectin. Second, the concentrations of these forms of P-selectin in solution are unaffected by ultracentrifugation at 100,OOOg for 3 hours, conditions previously reported to sediment platelet microparticles." Third, the calculated level of P-selectin that would be microparticle-associated in plasma'' is three orders of magnitude less than the amount detected by ELISA! Finally, if the affinity-purified polyclonal anti-P-selectin antibody used for coating the solid phase in the P-selectin ELISA was capturing microparticles, then the fluid phase antibody should detect any major GP constituent of microparticles such as the GP IIb-IIIa or GP Ib-IX complexes.'' However, although several different anti-P-selectin antibodies can be used satisfactorily for the plasma P-selectin ELISA, MoAbs against GP IIb-IIIa or GP Ib-IX give only background measurements (Dunlop and Berndt, unpublished observations).
Given that platelets contain mRNA-encoding soluble Pselectin, it is probable that the secreted and plasma forms of P-selectin represent the alternatively spliced, soluble form of P-selectin lacking the transmembrane sequence encoded by exon 14. 6 However, several lines of evidence argue against this being the only explanation of our findings. Firstly, the slight smaller molecular weight could be accounted for by proteolytic cleavage from either the N-or C-terminus of membrane P-selectin or by slight differences in posttranslational modifications such as decreased glycosylation. Secondly, microparticles do not quantitatively sediment in undiluted plasma even though a previous study did show sedimentation of microparticles after diluting the plasma.'' Thirdly, some platelet perturbations such as complement fixation can generate microparticles relatively enriched in P-selectin. Finally, the alternatively spliced form of P-selectin transfected into ALT 20 cells is secreted and not packaged into the storage granules.*' Considering together the available evidence, it is possible that the soluble form of P-selectin in plasma could coexist with P-selectin on microparticles but the relative proportions of each form need to be further investigated.
In addition to characterization ofthe secreted and plasma forms of P-selectin, we also studied plasma P-selectin in conjunction with PTG in healthy individuals and patients with consumptive platelet disorders. We observed among the healthy controls slightly higher plasma P-selectin and PTG concentrations in those more than 60 years of age, consistent with a previous report that found that plasma PTG levels increased with age.22 These observations might possibly be explained by the higher incidence of subclinical vascular disease in apparently healthy elderly individuals. However, the more striking finding, which has not previously been reported, was the significant and often marked increase in plasma P-selectin levels that occurred in parallel with increased plasma PTG levels in patients with DIC, TTP/HUS, and HIT. There was little overlap between the values of these patient groups and the age-matched healthy control group. The increased plasma P-selectin and PTG levels in patients with these thrombotic disorders may be the result of activation or damage of platelets and endothelial cells. In contrast, the lack of increased plasma P-selectin and PTG in patients with ITP may reflect the infrequent occurrence of in vivo platelet activation and endothelial cell perturbation in this condition.
Additionally, we found that plasma P-selectin measurement, unlike plasma PTG and PF4 assays, was not influenced by omission of the cumbersome measures customarily taken to prevent in vitro platelet activation during blood collection and sample preparation. Furthermore, Sodium heparin (5,000 U ) was administered intravenously to 3 subjects as a bolus. Blood was taken before and at 5 minutes and 40 minutes after the heparin injection and plasma P-selectin levels were estimated.
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From plasma P-selectin concentrations were not increased by intravenous heparin administration, which is known to increase plasma PF4 concentrations by about 30-f0ld;~ nor were they affected by renal insufficiency, as is the case with plasma /YTG le~els.2~ Our overall results and the recent observations by Wu et a12' of increased plasma P-selectin in patients with acute myocardial infarction and stroke suggest that plasma P-selectin is a convenient and useful marker for thrombotic diseases, particularly those with platelet/endothelial cell activation or damage.
